SOUTH SAN FRANCISCO, Calif.,
Nov. 13, 2019 /PRNewswire/ -- Rigel
Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that
Dean Schorno, the company's chief
financial officer, is scheduled to present a company overview at
the Jefferies 2019 London Healthcare Conference on Thursday, November 21, 2019 at 4:40pm GMT.
To access the live webcast of the presentation or the subsequent
archived recording, log on to www.rigel.com. Please connect to
Rigel's website several minutes prior to the start of the live
webcast to ensure adequate time for any software download that may
be necessary.
About Rigel (www.rigel.com)
Rigel Pharmaceuticals,
Inc., is a biotechnology company dedicated to discovering,
developing and providing novel small molecule drugs that
significantly improve the lives of patients with immune and
hematologic disorders, cancer and rare diseases. Rigel's pioneering
research focuses on signaling pathways that are critical to disease
mechanisms. The company's first FDA approved product is
TAVALISSE® (fostamatinib disodium hexahydrate) tablets,
the only oral spleen tyrosine kinase (SYK) inhibitor for the
treatment of adult patients with chronic immune thrombocytopenia
who have had an insufficient response to a previous treatment.
Rigel's current clinical programs include a Phase 3 study of
TAVALISSE in autoimmune hemolytic anemia (AIHA); a recently
completed Phase 1 study of R835, a proprietary molecule from its
interleukin receptor associated kinase (IRAK) inhibitor program;
and an ongoing Phase 1 study of R552, a proprietary molecule from
its receptor-interacting protein kinase (RIP1) inhibitor program.
In addition, Rigel has product candidates in clinical development
with partners Aclaris Therapeutics, AstraZeneca, BerGenBio ASA, and
Daiichi Sankyo.
Please see www.TAVALISSE.com for full Prescribing
Information.
IR Contact: David Burke
Phone: 650.624.1232
Email: dburke@rigel.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/rigel-to-present-at-jefferies-2019-london-healthcare-conference-300957055.html
SOURCE Rigel Pharmaceuticals, Inc.